

Patented Discovery Platform

ProMIS has developed a unique technology platform that allows its scientists to map out molecular targets with precision, allowing for the development of antibodies that recognize and bind specifically to those targets.

Neurodegenerative Diseases

- Traditional methods to develop antibodies cannot produce therapies that bind toxic oligomers with adequate precision, leading to limited efficacy and dose-limiting side effects
- ProMIS' novel discovery and development platform offers exquisite precision for toxic oligomers yielding opportunities for effective disease-modifying therapies & vaccines for Alzheimer's, Parkinson's & ALS

COVID-19 Antibody Tests

- ProMIS & JV partner BCNI Labs have developed a highly accurate serology assay to detect antibodies to the COVID-19 virus
- Test system offers potential to be cost-effective & high throughput
- ProMIS has identified 18 'targets' on COVID-19 spike protein and is evaluating if one or more of these can determine if detected antibodies neutralize the virus

Unique technology platform offers multiple opportunities for value creation *

Corporate Milestones	Q3 2020	Q4 2020	Q1 2021	Q2 2021	Q3 2021	Q4 2021
COVID-19 Serology/Immunity Assay	Scientific evaluation & assay development	Potential Revenue from multiple sources				
PMN310 – Best-in-class Alzheimer's Therapy	PMN310 IND enabling work (CMC – Manufacturing; GLP Toxicology)				Phase 1 clinical trials in AD Patients	
Neurodegenerative Disease Diagnostics	Equipment purchase & assay validation	Potential revenue from AD detection & diagnosis				
Alzheimer's Vaccine	Develop vaccine using ProMIS proprietary peptide antigens, pre-clinical validation, initiate IND-enabling work					

* Timelines contingent on availability of adequate capital

Integrated strategy to address Alzheimer's disease using ProMIS proprietary platform

Detect

ProMIS/BCNI Joint Venture
Create state-of-the-art diagnostic clinical platform for AD and other neurodegenerative diseases

Treat

PMN310
Provide best in class anti-amyloid therapeutic antibody that binds only toxic oligomers, not monomer or plaque

Prevent

Amyloid Vaccine
Devise safe, effective anti-amyloid and/or anti-tau vaccines to induce a specific immune response against toxic oligomers

Toxic amyloid accumulates over 20 to 30 years before cognitive symptoms
A substantial opportunity to detect disease, prevent further brain abnormalities and treat patients before symptoms appear

Competitive advantage over drugs in current or past clinical trials in AD (dark spots show binding). Toxic oligomers of amyloid are the target; off-target binding to monomer and/or fibrils (plaque) leads to lack of effect and/or significant side effects (brain swelling).

PMN310 binds selectively to the toxic oligomers

Bapineuzumab (Pfizer)

Solanezumab (Eli Lilly)

Aducanumab (Biogen)

PMN310 (ProMIS)

Phase 2 & 3 failure
Brain swelling side effect

Phase 2 & 3 failure


Phase 2 & 3 success
Brain swelling side effect

**Selective oligomer binding
Expected efficacy/safety
improvement**

Monomers

Fibrils


Oligomers





ProMIS has developed a highly accurate test for antibodies arising from COVID-19 infection or in response to vaccination. ProMIS proprietary targets (also called peptide antigens) on spike protein may allow to determine if detected antibodies neutralize the virus

PROMIS ASSAY



COVID-19 Immunity is complex

- Cellular (T-cells) vs humoral (antibodies)
 - High variability
 - Quality of immunity after COVID infection
 - Quality of immunity after vaccination
 - Duration of immunity (months, years?)
 - Immunity in elderly, other subgroups
 - Infection may not lead to immunity from re-infection
- ❖ **ProMIS assay to provide answers**

The ProMIS Leadership Team has over 150 years collective experience.

Name	Title	Years of Experience	Prior Experience
Gene Williams	Executive Chairman	25+	<ul style="list-style-type: none"> • Former SVP at Genzyme, with senior roles integrating commercialization, drug development, and deal making • Recently the CEO of Dart Therapeutics, an Orphan Disease drug development company • Founder and director of Adheris, which became the largest company in the patient adherence/compliance area
Elliot Goldstein	CEO	25+	<ul style="list-style-type: none"> • Held positions as SVP of Strategic Product Development at SmithKline Beecham (now GSK) • Chief Operating Officer and Chief Medical Officer of Maxygen • Chief Operating Officer at DART Therapeutics
Neil Cashman	Chief Science Officer	25+	<ul style="list-style-type: none"> • Holds the Canada Research Chair in Neurodegeneration and Protein Misfolding Diseases, • Serves as the Director of the University of British Columbia ALS Centre, • Awarded the Jonas Salk Prize for biomedical research in 2000
Steven Plotkin	Chief Physics Officer	20	<ul style="list-style-type: none"> • Professor at UBC in the Department of Physics and Astronomy since 2001 • Appointed as the Canada Research Chair in Theoretical Molecular Biophysics • Associate member of the Genome Sciences and Technology Program, the Bioinformatics Program, and the Institute for Applied Mathematics at the University of British Columbia
Dan Geffken	CFO	25+	<ul style="list-style-type: none"> • Founding Managing Director of Danforth Advisors • Served as the Chief financial officer of Homology, Inc, GenePeeks, Inc., Transkaryotic Therapies, Inc., Cidara, Inc., Apellis, Inc. and Stealth BioTherapeutics, Inc.
Johanne Kaplan	Chief Development Officer	25+	<ul style="list-style-type: none"> • Former VP of Research at Genzyme • Associate Immunopathologist at SmithKline Beecham where she established an Immunotoxicology program • Her work has resulted in over 60 scientific publications and multiple patents
James Kupiec	Chief Medical Officer	25+	<ul style="list-style-type: none"> • Former VP, Global Clinical Leader for Parkinson's disease, and Clinical Head of the Neuroscience Research Unit for Pfizer, Inc • Clinical focus on development of therapies for neurodegenerative disorders • Held positions at Sanofi-Synthelabo and Ciba-Geigy Pharmaceuticals

For more information please visit: www.promisneurosciences.com

Contact: eugene.williams@promisneurosciences.com or elliott.goldstein@promisneurosciences.com

Forward looking statement: safe harbor

This slide deck may contain certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this slide deck. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings available online at www.sedar.com. Actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

